Halozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of...
Tuesday, June 12, 2012, 12:55 PM ETHalozyme Therapeutics (HALO +4.4%) moves up after saying results from a Phase 2 study of rHuPH20, a prandial insulin, met its primary endpoint for blood sugar measurement in patients with Type 1 diabetes. Additionally, data from the study further indicated that rHuPH20 also reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles